The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.

President Trump has threatened to slap a 200% tariff on foreign-made pharmaceuticals. That would roil the $200 billion-plus ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds ...

Market OutlineThe Global Cell Isolation Market is valued at USD 15.6 Billion in 2024 and is projected to attain a value of USD 60.56 Billion by 2035 at a CAGR of 13.15% during the forecast period 2025 ...

StudyFormycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 10.07.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

As chief executive of Elon Musk's X, Linda Yaccarino navigated two turbulent years of charm offensives and legal threats to stabilize a bruised business-just in time for Musk's merger of X with xAI.

(Alliance News) - Water utility Severn Trent and housebuilder Vistry backed guidance, while advertising firm WPP named a new chief executive. Here is what you need to know before the London market ...

OSLO, Norway and CAMBRIDGE, MA, USA I July 9, 2025 I Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into ...

Mobile’s acquisition of U.S. Cellular, but the chief of the Antitrust Division is warning of industry concentration. Gail ...

The U.S. antitrust enforcers greenlit T-Mobile's $4.4 billion acquisition of UScellular on Thursday, saying that while ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...